The effect of the structure of branched polypeptide carrier on intracellular delivery of daunomycin

Biochimica et Biophysica Acta - Biomembranes

Volumn 1758, Issue 3, 2006, Pages 280-289

  Reményi, Judit ^a   Csík, Gabriella ^b   Kovács, Péter ^b   Reig, Francesca ^c   Hudecz, Ferenc ^a,d  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c DEPARTMENT OF ENVIRONMENTAL CHEMISTRY   (Spain)

^d EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Altered conjugate cytotoxicity; Daunomycin; pH dependent drug liberation; Polypeptide carrier; Uptake of daunomycin conjugate

Indexed keywords

ACID; DAUNORUBICIN; DIPALMITOYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; POLYCATION; POLYPEPTIDE; DRUG DERIVATIVE; LIPOSOME; N ACONITYLDAUNORUBICIN; N-ACONITYLDAUNOMYCIN; PEPTIDE; POLY(LYSYL (GLUTAMYL(I) ALANINE(M))); POLY(LYSYL(SERYL(I) ALANYL(M))); POLY(LYSYL(SERYL(I)-ALANYL(M))); POLY(LYSYL-(GLUTAMYL(I)-ALANINE(M))); PROTEIN;

ANIMAL CELL; ARTICLE; CELL LEVEL; CELL STRAIN HL 60; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; COMPREHENSION; CONJUGATE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RELEASE; DRUG STRUCTURE; DRUG UPTAKE; FLUORESCENCE; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PHOSPHOLIPID BILAYER; PRIORITY JOURNAL; TUMOR CELL; ANIMAL; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; LEUKEMIA L 1210; METABOLISM; PROMYELOCYTIC LEUKEMIA;

SERI;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANIMALS; DAUNORUBICIN; DRUG CARRIERS; HL-60 CELLS; HUMANS; LEUKEMIA L1210; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIPOSOMES; MICE; MOLECULAR STRUCTURE; PEPTIDES; PROTEINS; TUMOR CELLS, CULTURED;

EID: 33747056382     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2005.12.008     Document Type: Article

References (38)

1. Takakura Y., and Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit. Rev. Oncol. Hematol. 18 (1995) 207-231
2. Hudecz F., Kóczán G., and Reményi J. Peptide or protein based delivery and targeting. In: Keri G., and Toth I. (Eds). Molecular Pathomechanisms and New Trends in Drug Research (2003), Taylor and Francis Group, London 553-578
3. Duncan R. The dawning era of polymer therapeutics. Nat. Rev., Drug Discov. 2 (2003) 347-360
4. Ryser H.J., and Shen W.C. Conjugation of methotrexate to poly(l-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 3867-3870
5. Rosenkranz A.A., Yachmenev S.V., Jans D.A., Serebryakova N.V., Murav'ev V.I., Peters R., and Sobolev A.S. Receptor-mediated endocytosis and nuclear transport of a transfecting DNA construct. Exp. Cell Res. 199 (1992) 323-329
6. Hudecz F. Design of synthetic branched-chain polypeptides as carriers for bioactive molecules. Anticancer Drugs 6 (1995) 171-193
7. Mezo{combining double acute accent} G., Kajtár J., Nagy I., Majer Z., Szekerke M., and Hudecz F. Carrier design: synthesis and conformational studies of poly[l-lysine] based branched polypeptides with hydroxyl groups. Biopolymers 42 (1997) 719-730
8. Hudecz F., Pimm M.V., Rajnavölgyi E., Mezo{combining double acute accent} G., Fabra A., Gaal D., Kovacs A.L., Horvath A., and Szekerke M. Carrier design: new generation of polycationic branched polypeptides containing OH groups with prolonged blood survival and diminished in vitro cytotoxicity. Bioconjug. Chem. 10 (1999) 781-790
9. Clegg J.A., Hudecz F., Mezo{combining double acute accent} G., Pimm M.V., Szekerke M., and Baldwin R.W. Carrier design: biodistribution of branched polypeptides with a poly(l-lysine) backbone. Bioconjug. Chem. 1 (1990) 425-430
10. Nagy I.B., Hudecz F., Alsina M.A., and Reig F. Physicochemical characterization of branched chain polymeric polypeptide carriers based on a poly-lysine backbone. Biopolymers 70 (2003) 323-335
11. Hudecz F., Clegg J.A., Kajtár J., Embleton M.J., Szekerke M., and Baldwin R.W. Synthesis, conformation, biodistribution, and in vitro cytotoxicity of daunomycin-branched polypeptide conjugates. Bioconjug. Chem. 3 (1992) 49-57
12. Hudecz F., Reményi J., Szabó R., Kóczán G., Mezo{combining double acute accent} G., Kovács P., and Gaál D. Drug targeting by macromolecules without recognition unit?. J. Mol. Recognit. 16 (2003) 288-298
13. Hudecz F., Clegg J.A., Kajtár J., Embleton M.J., Pimm M.V., Szekerke M., and Baldwin R.W. Influence of carrier on biodistribution and in vitro cytotoxicity of methotrexate-branched polypeptide conjugates. Bioconjug. Chem. 4 (1993) 25-33
14. Kóczán G., Ghose A.C., Mookerjee A., and Hudecz F. Methotrexate conjugate with branched polypeptide influences Leishmania donovani infection in vitro and in experimental animals. Bioconjug. Chem. 13 (2002) 518-524
15. Mezo{combining double acute accent} G., Mezo{combining double acute accent} I., Pimm M.V., Kajtar J., Sepro{combining double acute accent}di J., Teplán I., Kovács M., Vincze B., Palyi I., Idei M., Szekerke M., and Hudecz F. Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate. Bioconjug. Chem. 7 (1996) 642-650
16. Pató J., Ulbrich K., Baker P., Mezo{combining double acute accent} G., and Hudecz F. Synthesis of macromolecular conjugates of an urokinase inhibitor. J. Bioact. Comp. Polym. 14 (1999) 99-121
17. 99mTc-branched chain polypeptide (BCP): a potential synthetic radiopharmaceutical. J. Labelled Compd. 41 (1998) 631-638
18. 51Cr) for biodistribution studies and radiopharmaceutical development. J. Labelled Compd. 36 (1995) 157-172
19. Hudecz F. Manipulation of epitope function by modification of peptide structure: a minireview. Biologicals 29 (2001) 197-207
20. Sospedra P., Nagy I.B., Haro I., Mestres C., Hudecz F., and Reig F. Physicochemical behaviour of polylysine[HAV-VP3 peptide] constructs at the air-water interface. Langmuir 15 (1999) 5111-5117
21. Nagy I.B., Alsina M.A., Haro I., Reig F., and Hudecz F. Phospholipid-model membrane interactions with branched polypeptide conjugates of a hepatitis A virus peptide epitope. Bioconjug. Chem. 11 (2000) 30-38
22. Gaal D., and Hudecz F. Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide. Eur. J. Cancer 34 (1998) 155-161
23. Votavova H., Hudecz F., Kajtár J., Szekerke M., Sponar J., and Bláha K. Coll. Czech. Chem. Comm. 45 (1980) 941-949
24. Nagy I.B., Majer Z., and Hudecz F. Effect of phospholipid bilayers on solution conformation of branched polymeric polypeptides and peptide-polymer conjugates. Biopolymers 58 (2001) 152-164
25. Nagy I.B., Haro I., Alsina M.A., Reig F., and Hudecz F. Interaction of branched chain polymeric polypeptides with phospholipids model membranes. Biopolymers 46 (1998) 169-179
26. Kuhry J.G., Duportail G., Bronner C., and Laustriat G. Plasma membrane fluidity measurements on whole living cells by fluorescence anisotropy of trimethylammoniumdiphenylhexatriene. Biochim. Biophys. Acta 845 (1985) 60-67
27. King H.D., Staab A.J., Pham-Kaplita K., Yurgaitis D., Firestone R.A., Lasch S.J., and Trail P.A. BR96 conjugates of highly potent anthracyclines. Bioorg. Med. Chem. Lett. 13 (2003) 2119-2122
28. Harada M., Sakakibara H., Yano T., Suzuki T., and Okuno S. Determinants for the drug release from T-0128, camptothecin analogue-carboxymethyl dextran conjugate. J. Control. Release 69 (2000) 399-412
29. Etrych T., Jelinkova M., Rihova B., and Ulbrich K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J. Control. Release 73 (2001) 89-102
30. Calzolai L., Gaggelli E., Maccotta A., and Valensin G. 228-235, Interaction of daunomycin with dipalmitoylphosphatidylcholine model membranes. A H-1 NMR study. J. Magn. Reson. Ser., B 112 (1996) 228-235
31. Canaves J.M., Ferragut J.A., and Gonzalez-Ros J.M. Verapamil prevents the effects of daunomycin on the thermotropic phase transition of model lipid bilayers. Biochem. J. 279 Pt 2 (1991) 413-418
32. Pezeshk A., Wojas J., and Subczynski W.K. Partitioning and structural effects of the antitumor drug daunomycin on model membranes. Life Sci. 63 (1998) 1863-1870
33. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57 (1999) 727-741
34. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3 (1992) 175-210
35. Kratz F., Beyer U., Roth T., Tarasova N., Collery P., Lechenault F., Cazabat A., Schumacher P., Unger C., and Falken U. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci. 87 (1998) 338-346
36. Rodrigues P.C., Beyer U., Schumacher P., Roth T., Fiebig H.H., Unger C., Messori L., Orioli P., Paper D.H., Mulhaupt R., and Kratz F. Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Bioorg. Med. Chem. 7 (1999) 2517-2524
37. Hovorka O., St'astny M., Etrych T., Subr V., Strohalm J., Ulbrich K., and Rihova B. Differences in the intracellular fate of free and polymer-bound doxorubicin. J. Control. Release 80 (2002) 101-117
38. Omelyanenko V., Kopeckova P., Gentry C., and Kopecek J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release 53 (1998) 25-37